p53 Primary Antibody

Item Information
Catalog #Size/ConcentrationPrice
Specification
AliasesLFS1, TRP53, TP53
ProductOrderP
Clone#4A8
Entrez GenelD7157
FormulationAscitic fluid containing 0.03% sodium azide.
HostMouse
IsotypeIgG1
ImmunogenPurified recombinant fragment of human p53 expressed in E. Coli.
MW43.7kDa
Shipping InformationThis product will ship in a box containing blue ice at a temperature of 4°C. Learn More
Species ReactivityHuman
Application
ELISA1/10000
IHC_P(Immunohistochemistry)1/200 - 1/1000
WB (Western Blot)1/500 - 1/2000
Sequence
full
Catalog#: 20338
Inquire
Contact us to order
Images
Western Blot
Figure 1: Western blot analysis using p53 mouse mAb against HEK293 cell lysate(1).
Figure 1: Western blot analysis using p53 mouse mAb against HEK293 cell lysate(1).
Immunohistochemical analysis
Figure 2: Immunohistochemical analysis of paraffin-embedded human esophageal cancer (left) and lung cancer (right), showing nuclear localization using p53 mouse mAb with DAB staining.
Figure 2: Immunohistochemical analysis of paraffin-embedded human esophageal cancer (left) and lung cancer (right), showing nuclear localization using p53 mouse mAb with DAB staining.
Product Overview
Description

p53 responds to diverse cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing transcription activation, DNA-binding, and oligomerization domains. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of this gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome. Multiple p53 variants due to alternative promoters and multiple alternative splicing have been found. These variants encode distinct isoforms, which can regulate p53 transcriptional activity.

References (references)
References (references)1. Cancer Invest. 2009 Jan;27(1):96-104.
2. Anticancer Res. 2007 Nov-Dec;27(6B):4143-8.
3. Mol Cell. 2008 Feb 1;29(2):217-31.